BioSpace News Archive

Pharm Country

Wills Eye Hospital Announces $5 Million Gift for Vision Research - Ushering in New Era of Scientific Advancements

Hospital’s Vision Research Department is renamed The Vickie and Jack Farber Vision Research Center at Wills Eye

July 2, 2018
·
4 min read
Policy

SmileDirectClub Releases Statement Regarding Update in Ongoing Proceedings with Align Technology

SmileDirectClub today released a statement responding to the recent ruling in their ongoing proceedings with Align Technology:

July 2, 2018
·
1 min read
Business

Lawyer Joseph “Joe” Awad Set for MENSA Annual Conference Keynote on Med Malpractice Epidemic

New York’s Best Known Medical Malpractice Lawyer to Present: “Malpractice Inc. - Surviving U.S. Profits-before-Patients Healthcare” at MENSA Event

July 2, 2018
·
2 min read
New Radiotherapy Prostate Cancer Treatment, SpaceOAR® Hydrogel, Now Available in Japan

Augmenix K.K. announces that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all prostate cancer radiotherapy patients in Japan through the Ministry of Health, Labour & Welfare (MHLW) national reimbursement.

July 2, 2018
·
4 min read
Drug Development

Roche’s Tecentriq Looks Encouraging for Triple-Negative Breast Cancer

Roche announced that its Phase III IMpassion130 clinical trial met its co-primary endpoint of progression-free survival (PFS) in triple-negative breast cancer (TNBC).

July 2, 2018
·
3 min read
·
Mark Terry
FDA

Alkermes Scores FDA Approval for Potential Game-Changing Schizophrenia Treatment

Shares of Alkermes plc are climbing in premarket trading after the company announced the U.S. Food and Drug Administration approved Aristada Initio (aripiprazole lauroxil) as part of a combination treatment for schizophrenia.

July 2, 2018
·
3 min read
·
Alex Keown
Business

Deborah Dunsire Takes Over as CEO of Denmark’s H. Lundbeck

Former XTuit Pharmaceuticals Chief Executive Officer Deborah Dunsire has been appointed head of Denmark-based H. Lundbeck A/S.

July 2, 2018
·
2 min read
·
Alex Keown
Biotech Beach

Adamis Pharma Sells Epinephrine Injector Rights to Novartis

Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.

July 2, 2018
·
3 min read
·
Mark Terry
Business

Athenex Scores $100 Million in Financing, Kicks off Joint Venture in China for Development of TCR T Cells

Athenex is kicking off the second half of 2018 with a bang. The company secured $100 million in investments from Perceptive Advisors, is making major inroads in China with a joint venture with Chinese biotech Xiangxue Life Sciences and an in-licensing agreement from Avalon PolyTom Limited.

July 2, 2018
·
3 min read
·
Alex Keown
Drug Development

Record Year So Far for Massachusetts Biotech IPOs

It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.

July 2, 2018
·
4 min read
·
Mark Terry